Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-15
2005-03-15
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S080000, C514S410000, C514S415000, C514S429000, C548S400000, C548S452000, C548S469000, C548S503000, C548S511000, C548S509000
Reexamination Certificate
active
06867200
ABSTRACT:
The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
REFERENCES:
patent: 273418 (1988-07-01), None
patent: 192152 (1984-04-01), None
patent: 02306916 (1990-12-01), None
patent: WO 9822619 (1998-05-01), None
patent: 9822619 (1998-05-01), None
patent: WO 9926933 (1999-06-01), None
patent: WO 9926941 (1999-06-01), None
Chem. Abstract DN 110:85613, aslo cited as EP 273418.*
Chem. Abstract DN 10(:190304.*
Iwanowicz et al, Bioorg & Med. Chem. Letters 6/12, 1339-44(1996).*
Cecil Textbook of Medicine, Edited by Bennett & Plum, 1996, pp. 1004-1010.*
Uckum, et al,“Structure-based Design of Novel Anti-cancer Agts”, Current Drg Targets,1,59-71(2001).*
Kaneko et al,PubMed.Abstract12708473, also cites as Cancer Sci., Urokinase-type plasminogen activator expr . . . , 94/1, 43-9(2003).*
Gronefeld et al, “Thromboempolic risk of Patients referred for radiofrequency.”, PubMed Abstract 12687838, also cited as Pacin Clin. Electrophysiol., 26/1, 323-7(2003).*
De Lorenzo et al, PubMed Abstract 12656654, also cited as Drugs., :Blood Coagulation in patients., 63/6,565-76(2003).*
Chemical Abstrac DN 110:85613, also cited as EP 273418 See CAS RN # 118234-55-2.*
McKinnon et al, Chemical Abstract DN 109:190304, also cited as Canadian J. Chem. 66/6, 1405-9(1988).*
Iwanowicz et al, Boorg & Med Chem Letr. 6/12, 1339-44 (1996).*
Tidwell R.R. et al. “Diarylamidine derivatives with one or both of th earyl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases”J. Med. Chem. 1978, 21(7), 613-623.
Nishi T. et al. “Preparation of benzothiazoles and benzimidazoles as blood platelet aggregation inhibitors” Chemical Abstracts 1991, 114(21), 832.
Iwanowicz E.J. et al. “Derivatives of 5-amidine indole as inhibitors of thrombin catalytic activity”Bioorganic&Medicinal Chemistry Letters1996, 6(12), 1339-1344.
Katz B.A. et al. “Design of potent selective zinc-mediated serine protease inhibitors”Nature1998, 391, 608-612.
Allen Darin A.
Hataye Jason M.
Hruzewicz Witold N.
Jeffrey Spencer R.
Kolesnikov Aleksandr
Axys Pharmaceuticals Inc.
Patel Sudhaker B.
Raymond Richard L.
Townsend and Townsend / and Crew LLP
LandOfFree
(Hetero)aryl-bicyclic heteroaryl derivatives, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Hetero)aryl-bicyclic heteroaryl derivatives, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Hetero)aryl-bicyclic heteroaryl derivatives, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392449